Search

Your search keyword '"Klautke, G."' showing total 13 results
Start Over Author "Klautke, G." Publisher elsevier b.v.
13 results on '"Klautke, G."'

4. Impact of comorbidity and age on the outcome of patients with inoperable NSCLC treated with concurrent chemoradiotherapy.

Author

Semrau, S., Klautke, G., Virchow, J.C., Kundt, G., and Fietkau, R.

Abstract

Summary: Background: The value of concurrent chemoradiotherapy (CRT) for treatment of locally advanced non-small cell lung cancer (NSCLC) in elderly and multimorbid patients is generally disputed due to the assumed lack of toxicity compensation or the limited prognosis of the accompanying morbidity. Aim: We investigated correlation between impaired organ function, age, tumor-associated symptoms, social factors and acute toxicity as well as survival following CRT. Patients and methods: Retrospective data collection and analysis were performed on the variables age, functional parameters: FEV1, VC, DLCO, LVEF, creatinine clearance, age, several categories of comorbidities, WHO performance status, alcohol and nicotine habits, toxicity according CTC-criteria and survival of all patients (n=66) with inoperable NSCLC suffering substantial comorbidities or advanced age (>70 years) treated with an CRT consisting of two cycles cisplatin or carboplatin plus vinorelbine and a conventionally fractionated radiotherapy up to 63Gy. Results: Median survival of all patients was 13 months (10.6–15.4 months, 95% confidence interval). Univariate analyses showed significantly poorer survival (12 months vs. 15 months) in patients with LVEF<50% compared with LVEF⩾50% (P=0.022, in log-rank test). All other variables did not exhibit any significant correlation to survival. Multivariate analyses revealed significantly inferior survival in patients suffering from cardiac or pulmonary dysfunction (P=0.039, hazard ratio [HR]: 2.18; 95% CI of HR [1.04–4.59]). Elderly patients (>70 years) had a higher prevalence of hematotoxicity of higher degree than younger patients (⩽70 years), but without significant impact on the feasibility of both treatment modalities. Conclusion: Our results suggest that cardiac and pulmonary dysfunction may be associated with a reduced survival in elderly or poor-risk patients with inoperable NSCLC after CRT. [Copyright &y& Elsevier]

Published
2008
Full Text
View/download PDF

5. 873P Nivolumab (NIVO) in the first-line (1L) or second-line (2L) and later (2L+) settings in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Updated results from the German non-interventional study (NIS), HANNA

Author

Dietz, A., Hahn, D.A., Langer, C., Kubuschok, B., Bockmühl, U., Mueller-Huesmann, H., Klautke, G., Reuter, B., Grün, J. von der, Beutner, D., Büntzel, J., Busch, C-J., Tamaskovics, B.F., Riera Knorrenschild, J., Welslau, M.K., Gauler, T.C., Waldenberger, D., and Von der heyde, E.

Subjects
*SQUAMOUS cell carcinoma, *NIVOLUMAB, *NECK, *METASTASIS, *HEAD
Published
2024
Full Text
View/download PDF

7. 944TiP Randomized phase II study of immune stimulation with pembrolizumab and radiotherapy of recurrent and/or metastatic head and neck squamous cell carcinoma : The IMPORTANCE trial.

Author

Tamaskovics, B.F., Hecht, M., Schubert, P., Kallies, A., Illmer, T., Radke, J., Koelbl, O., Steger, F., Brunner, T.B., Rödel, C., Fleischmann, M., Reinacher-Schick, A., Wingender, L.F., Melchior, P., Klautke, G., Hintzen, U., Gaipl, U.S., Haussmann, J., Budach, W., and Fietkau, R.

Subjects
*SQUAMOUS cell carcinoma, *NECK, *PEMBROLIZUMAB, *METASTASIS, *RADIOTHERAPY, *HEAD
Published
2023
Full Text
View/download PDF

8. 680P HANNA: Real-world data of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), including first-line population, treated with nivolumab in Germany.

Author

Langer, C., von der Heyde, E., Hahn, D.A., Kubuschok, B., Bockmühl, U., Mueller-Huesmann, H., Klautke, G., von der Grün, J., Beutner, D., Büntzel, J., Busch, C-J., Tamaskovics, B.F., Riera Knorrenschild, J., Gutsche, K., Welslau, M.K., Gauler, T.C., Waldenberger, D., and Dietz, A.

Subjects
*SQUAMOUS cell carcinoma, *NIVOLUMAB, *NECK, *METASTASIS, *HEAD
Published
2022
Full Text
View/download PDF

9. O-011 - Randomized phase 2 trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12.

Author

Hofheinz, R., Fokas, E., Allgäuer, M., Polat, B., Klautke, G., Grabenbauer, G., Fietkau, R., Kuhnt, T., Staib, L., Brunner, T., Grosu, A., Schmiegel, W., Jacobasch, L., Weitz, J., Folprecht, G., Germer, C., Grützmann, R., Schwarzbach, M., Bechstein, W., and Friede, T.

Subjects
*NEOADJUVANT chemotherapy, *CONSOLIDATION chemotherapy, *CHEMORADIOTHERAPY, *INDUCTION chemotherapy, *RECTAL cancer
Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results